Amber Tong

China has started cracking down on unlicensed production and sale of medicines similar to Novo Nordisk A/S 's blockbuster diabetes and obesity treatment, in a bid to curb a gray market that caters to growing demand for such therapies amid a global supply crunch.

China has started cracking down on unlicensed production and sale of medicines similar to Novo Nordisk A/S’s blockbuster diabetes and obesity treatment, in a bid to curb a gray market that caters to growing demand for such therapies amid a global supply crunch.

China has started cracking down on unlicensed production and sale of medicines similar to Novo Nordisk A/S’s blockbuster diabetes and obesity treatment, in a bid to curb a gray market that caters to growing demand for such therapies amid a global supply crunch.

Pfizer Inc. said it will push ahead with its sickle cell drug candidates, despite its decision to withdraw an approved treatment for the disease after higher-than-acceptable patient deaths and complications in clinical trials.

In the ADC renaissance of the last few years, Japan … Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

An elderly patient died in a clinical study of Roche Holding AG’s experimental treatment for Alzheimer’s disease, prompting changes to the trial design, although the company said overall results support further testing.

An elderly patient died in a clinical study of Roche's experimental treatment for Alzheimer's disease, prompting changes to the trial design, although the company said overall results support further testing.

China’s probe into AstraZeneca Plc has reached its uppermost echelons, ensnaring local president Leon Wang and throwing into question the future of the most successful Western pharmaceutical company in the country.

China’s leading innovative cancer drugmaker BeiGene Ltd. plans to change its name to BeOne Medicines as part of a rebranding to support its growth ambitions in markets including the US and Europe.